⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OVID News
Ovid Therapeutics Inc. Common Stock
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
globenewswire.com
OVID
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
globenewswire.com
OVID